Application of intestinal bacteria in medicine or biological preparation for preventing or treating nephrotic syndrome
The invention belongs to the technical field of clinical medicine, and discloses application of intestinal bacteria in drugs or biological preparations for preventing or treating nephrotic syndromes. Specific intestinal bacteria species are closely related to occurrence and development of the immune-mediated nephrotic syndrome, abnormal changes of the bacteria in intestinal tracts can induce occurrence of the immune-mediated nephrotic syndrome, and disease progression can be aggravated after nephropathy occurs. According to the 21 kinds of bacteria provided by the invention, the relative content of 12 kinds of immune-mediated nephrotic syndrome patients in intestinal tracts is reduced and is closely related to pathogenesis. The other nine bacteria comprise AKK bacteria and the like, and the relative expression quantity of the nine bacteria in the intestinal tract of the immune-mediated nephrotic syndrome patient is in significant negative correlation with the clinical adverse indexes of the immune-mediated nephrotic syndrome. Any one or a combination of more of the 22 bacteria is supplemented to a patient suffering from the immune-mediated nephrotic syndrome, so that the effect of treating or adjunctively treating the immune-mediated nephrotic syndrome is achieved..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 27. Okt. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG SEN [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-10-27, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 |
|---|
| Patentnummer: |
CN116942707 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA003852237 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA003852237 | ||
| 003 | DE-627 | ||
| 005 | 20240426160437.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240426s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA003852237 | ||
| 035 | |a (EPA)CN116942707 | ||
| 035 | |a (EPA)88443073 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG SEN |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Application of intestinal bacteria in medicine or biological preparation for preventing or treating nephrotic syndrome |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-10-27, Last update posted on www.tib.eu: 2024-04-22, Last updated: 2024-04-26 | ||
| 520 | |a The invention belongs to the technical field of clinical medicine, and discloses application of intestinal bacteria in drugs or biological preparations for preventing or treating nephrotic syndromes. Specific intestinal bacteria species are closely related to occurrence and development of the immune-mediated nephrotic syndrome, abnormal changes of the bacteria in intestinal tracts can induce occurrence of the immune-mediated nephrotic syndrome, and disease progression can be aggravated after nephropathy occurs. According to the 21 kinds of bacteria provided by the invention, the relative content of 12 kinds of immune-mediated nephrotic syndrome patients in intestinal tracts is reduced and is closely related to pathogenesis. The other nine bacteria comprise AKK bacteria and the like, and the relative expression quantity of the nine bacteria in the intestinal tract of the immune-mediated nephrotic syndrome patient is in significant negative correlation with the clinical adverse indexes of the immune-mediated nephrotic syndrome. Any one or a combination of more of the 22 bacteria is supplemented to a patient suffering from the immune-mediated nephrotic syndrome, so that the effect of treating or adjunctively treating the immune-mediated nephrotic syndrome is achieved. | ||
| 650 | 4 | |a bio | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a C12R: Indexing scheme associated with subclasses c12c-c12q, relating to microorganisms | |
| 650 | 4 | |a C12Q: Measuring or testing processes involving enzymes, nucleic acids or microorganisms (immunoassay g01n0033530000); compositions or test papers therefor; processes of preparing such compositions; condition-responsive control in microbiological or enzymological processes | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a SHI XIAOHU |e verfasserin |4 aut | |
| 700 | 0 | |a WANG YAN |e verfasserin |4 aut | |
| 700 | 0 | |a ZHANG DONGMING |e verfasserin |4 aut | |
| 700 | 0 | |a LI ZHAOJUN |e verfasserin |4 aut | |
| 700 | 0 | |a WU HAIJIE |e verfasserin |4 aut | |
| 700 | 0 | |a CHEN YUANYUAN |e verfasserin |4 aut | |
| 700 | 0 | |a ZHAO XIAODI |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 27. Okt. |
| 773 | 1 | 8 | |g year:2023 |g day:27 |g month:10 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/88443073/publication/CN116942707A1?q=CN116942707 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 27 |c 10 | ||